Adam Sragovicz - Conduit Pharmaceuticals Chief Officer
| CDT Stock | 0.11 0.01 11.00% |
Executive
Adam Sragovicz is Chief Officer of Conduit Pharmaceuticals
| Age | 54 |
| Address | 4995 Murphy Canyon Road, San Diego, CA, United States, 92123 |
| Phone | 760 471 8536 |
| Web | https://www.conduitpharma.com |
Adam Sragovicz Latest Insider Activity
Tracking and analyzing the buying and selling activities of Adam Sragovicz against Conduit Pharmaceuticals stock is an integral part of due diligence when investing in Conduit Pharmaceuticals. Adam Sragovicz insider activity provides valuable insight into whether Conduit Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Conduit Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Conduit Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Adam Sragovicz over two months ago Acquisition by Adam Sragovicz of 600 shares of Intellicheck Mobilisa at 2.03 subject to Rule 16b-3 | ||
Adam Sragovicz over six months ago Acquisition by Adam Sragovicz of 6494 shares of Presidio Property subject to Rule 16b-3 |
Conduit Pharmaceuticals Management Efficiency
The company has Return on Asset of (3.2202) % which means that on every $100 spent on assets, it lost $3.2202. This is way below average. Conduit Pharmaceuticals' management efficiency ratios could be used to measure how well Conduit Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.07 in 2024. Return On Capital Employed is likely to gain to -0.97 in 2024. At this time, Conduit Pharmaceuticals' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 7.6 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 5.7 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Troy Lister | Verve Therapeutics | N/A | |
| Kristin Stafford | Royalty Pharma Plc | 42 | |
| Paul MD | Sana Biotechnology | N/A | |
| Amy MD | Beam Therapeutics | 60 | |
| JD Esq | Caribou Biosciences | 69 | |
| Alexander Constan | Ikena Oncology | N/A | |
| John Thomas | Krystal Biotech | N/A | |
| Kathryn CPA | Krystal Biotech | 43 | |
| Amy CFA | Caribou Biosciences | N/A | |
| Richard Mulligan | Sana Biotechnology | 69 | |
| Biren Shah | Elevation Oncology | N/A | |
| Kevin CPA | Enveric Biosciences | 60 | |
| John MD | Sana Biotechnology | N/A | |
| Terry MD | Sana Biotechnology | 57 | |
| Ashwin MD | Royalty Pharma Plc | N/A | |
| Reigin Zawadzki | Caribou Biosciences | N/A | |
| Patrick Mayo | Hepion Pharmaceuticals | N/A | |
| Robert Yang | Elevation Oncology | N/A | |
| Christine Wilson | Krystal Biotech | N/A | |
| Robin Andrulevich | Sana Biotechnology | 58 | |
| Ryan Fischesser | Caribou Biosciences | N/A | |
Management Performance
| Return On Asset | -3.22 |
Conduit Pharmaceuticals Leadership Team
Elected by the shareholders, the Conduit Pharmaceuticals' board of directors comprises two types of representatives: Conduit Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Conduit. The board's role is to monitor Conduit Pharmaceuticals' management team and ensure that shareholders' interests are well served. Conduit Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Conduit Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Tapolczay, CEO Director | ||
| James Bligh, Interim Director | ||
| Adam Sragovicz, Chief Officer | ||
| Joanne Holland, Chief Officer | ||
| Bill Begien, Senior Relations |
Conduit Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Conduit Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -3.22 | ||||
| Current Valuation | 14.98 M | ||||
| Shares Outstanding | 116.8 M | ||||
| Shares Owned By Insiders | 49.11 % | ||||
| Shares Owned By Institutions | 4.05 % | ||||
| Number Of Shares Shorted | 2.36 M | ||||
| EBITDA | (324 K) | ||||
| Net Income | (535 K) | ||||
| Total Debt | 985 K | ||||
| Book Value Per Share | (0.01) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.